Genetic Modifiers in Sickle Cell Disease Leg Ulcers: Unveiling the Pathways associated with the development and/or progression of Leg Ulcers - A Scoping Review Protocol
Main Article Content
Keywords
Genetic, Genetic Modifiers, Markers, Genetic Biomarkers, Leg Ulcer, Scoping Review, Sickle Cell Disease, Sickle Cell
Abstract
Objective: This scoping review’s main objective is to assess the availability and types, methodologies utilized, quality of literature as well as gaps in research on genetic modifiers of leg ulcers in sickle cell disease with a view to determining the adequacy or otherwise of this literature in future evidence synthesis.
Introduction: A major morbidity in sickle cell disease is the development of leg ulcers. This clinical syndrome of SCD leg ulcers (SLU) has continued to be an enigma due to its multifactorial evolution, dearth of promising guidelines on treatment, and generally unsatisfactory response to treatment. Underlying genetic susceptibilities for SLU may impact counselling, prognostication, risk of development, severity as well as response to interventions. Hence the need for this scoping review.
Inclusion criteria: This scoping review will collate and assess all studies on genetic markers of SLU among all SCD age groups, genders, races, and regions.
Methods: A Pubmed search of all fields for literature published in English using the strategy (sickle cell) AND (leg ulcer) from 1998 to 2023 (last 25 years) will be undertaken. This will be modified, according to the inclusion criteria, as appropriate across other databases. The other databases will include Google Scholar, web of Knowledge, Scopus, New Zealand Science, Silverchair, Taylor and Francis+NEJM, and journals.lww.com.
References
2. Fraiwan A, Hasan MN, An R, Rezac AJ, Kocmich NJ, Oginni T, et al. Advancing Healthcare Outcomes for Sickle Cell Disease in Nigeria Using Mobile Health Tools. Blood 2019;134(Supplement_1):2173.
3. The Management of Sickle Cell Disease | NHLBI, NIH [Internet]. [cited 2022 Aug 9];Available from: https://www.nhlbi.nih.gov/resources/management-sickle-cell-disease
4. Inusa BPD, Hsu LL, Kohli N, Patel A, Ominu-Evbota K, Anie KA, et al. Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment. Int J Neonatal Screen 2019;5(2).
5. Nnodu OE, Oron AP, Sopekan A, Akaba GO, Piel FB, Chao DL. Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 Demographic and Health Survey. Lancet Haematol 2021;8(10):e723–31.
6. Makani J, Soka D, Rwezaula S, Krag M, Mghamba J, Ramaiya K, et al. Health policy for sickle cell disease in Africa: experience from Tanzania on interventions to reduce under-five mortality. Trop Med Int Health TM IH 2015;20(2):184–7.
7. Galadanci N, Wudil BJ, Balogun TM, Ogunrinde GO, Akinsulie A, Hasan-Hanga F, et al. Current sickle cell disease management practices in Nigeria. Int Health 2014;6(1):23–8.
8. Reis de Souza V, Kelly S, Cerdeira Sabino E, Mendes de Oliveira F, Silva T, Miranda Teixeira C, et al. Factors Associated with Leg Ulcers in Adults with Sickle Cell Disease in Brazil. Adv Skin Wound Care 2023;36(2):98–105.
9. de Carvalho-Siqueira GQ, Ananina G, de Souza BB, Borges MG, Ito MT, da Silva-Costa SM, et al. Whole-exome sequencing indicates FLG2 variant associated with leg ulcers in Brazilian sickle cell anemia patients. Exp Biol Med Maywood NJ 2019;244(11):932–9.
10. Olatunya OS, Albuquerque DM, Adekile A, Costa FF. Influence of alpha thalassemia on clinical and laboratory parameters among nigerian children with sickle cell anemia. J Clin Lab Anal 2019;33(2):e22656.
11. Santos E do C, Melo GIV, Santana PVB, Quadros IGS, Yahouédéhou SCMA, da Guarda CC, et al. A Description of the Hemolytic Component in Sickle Leg Ulcer: The Role of Circulating miR-199a-5p, miR-144, and miR-126. Biomolecules 2022;12(2):317.
12. Minniti CP, Eckman J, Sebastiani P, Steinberg MH, Ballas SK. Leg ulcers in sickle cell disease. Am J Hematol 2010;85(10):831–3.
13. Ladizinski B, Bazakas A, Mistry N, Alavi A, Sibbald RG, Salcido R. Sickle Cell Disease and Leg Ulcers. Adv Skin Wound Care 2012;25(9):420–8.
14. Damanhouri GA, Jarullah J, Marouf S, Hindawi SI, Mushtaq G, Kamal MA. Clinical biomarkers in sickle cell disease. Saudi J Biol Sci 2015;22(1):24–31.
15. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3):89–95.
16. Kalpatthi R, Novelli EM. Measuring success: utility of biomarkers in sickle cell disease clinical trials and care. Hematology 2018;2018(1):482–92.
17. Puntmann VO. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad Med J 2009;85(1008):538–45.
18. Rees DC, Gibson JS. Biomarkers in sickle cell disease. Br J Haematol 2012;156(4):433–45.
19. Schiavo JH. PROSPERO: An International Register of Systematic Review Protocols. Med Ref Serv Q 2019;38(2):171–80.
20. Pollock D, Davies EL, Peters MDJ, Tricco AC, Alexander L, McInerney P, et al. Undertaking a scoping review: A practical guide for nursing and midwifery students, clinicians, researchers, and academics. J Adv Nurs 2021;77(4):2102–13.
21. JBI Manual for Evidence Synthesis - JBI Global Wiki [Internet]. [cited 2024 Jul 9];Available from: https://jbi-global-wiki.refined.site/space/MANUAL
22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
23. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 2018;169(7):467–73.
24. My Library | Zotero [Internet]. [cited 2023 May 27];Available from: https://www.zotero.org/lgdogara/collections/E9WQ73PG
25. changelog [Zotero Documentation] [Internet]. [cited 2024 Sep 29];Available from: https://www.zotero.org/support/changelog
26. Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth 2020;18(10):2119–26.
27. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation | Annals of Internal Medicine [Internet]. [cited 2024 Sep 29];Available from: https://www.acpjournals.org/doi/10.7326/M18-0850
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.